Synapse

← Scott M. Grundy

Papers by Scott M. Grundy

Page 3 · newest first

  1. Primary Prevention of Cardiovascular Diseases in People With Diabetes MellitusDiabetes Care · 2006
  2. Gamma-Glutamyl TransferaseArteriosclerosis Thrombosis and Vascular Biology · 2006
  3. Influence of Body Fat Content and Distribution on Variation in Metabolic RiskThe Journal of Clinical Endocrinology & Metabolism · 2006
  4. Does the Metabolic Syndrome Exist?Diabetes Care · 2006
  5. Ethnic-Specific Criteria for the Metabolic SyndromeDiabetes Care · 2006
  6. Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and DiabetesDiabetes Care · 2006
  7. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 UpdateCirculation · 2006
  8. Role of Genetic Polymorphism Peroxisome Proliferator–Activated Receptor-γ2 Pro12Ala on Ethnic Susceptibility to Diabetes in South-Asian and Caucasian SubjectsDiabetes Care · 2006
  9. Diabetes and Coronary Risk EquivalencyDiabetes Care · 2006
  10. Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levelsProceedings of the National Academy of Sciences · 2006
  11. Relationship Between C-Reactive Protein and Subclinical AtherosclerosisCirculation · 2005
  12. The metabolic syndrome: a call to actionCoronary Artery Disease · 2005
  13. Diagnosis and management of the metabolic syndromeCurrent Opinion in Cardiology · 2005
  14. Diagnosis and Management of the Metabolic SyndromeCardiology in Review · 2005
  15. Diagnosis and Management of the Metabolic SyndromeCirculation · 2005
  16. Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemiaJournal of Lipid Research · 2005
  17. Joint Distribution of Non-HDL and LDL Cholesterol and Coronary Heart Disease Risk Prediction Among Individuals With and Without DiabetesDiabetes Care · 2005
  18. ENPP1/PC-1 K121Q Polymorphism and Genetic Susceptibility to Type 2 DiabetesDiabetes · 2005
  19. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary DiseaseNew England Journal of Medicine · 2005
  20. Atherosclerosis Imaging and the Future of Lipid ManagementCirculation · 2004
  21. Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of EthnicityHepatology · 2004
  22. No Association Between Plasma Levels of Plant Sterols and Atherosclerosis in Mice and MenArteriosclerosis Thrombosis and Vascular Biology · 2004
  23. Richard Havel, Howard Eder, and the evolution of lipoprotein analysisJournal of Clinical Investigation · 2004
  24. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general populationAJP Endocrinology and Metabolism · 2004
  25. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesArteriosclerosis Thrombosis and Vascular Biology · 2004
  26. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesCirculation · 2004
  27. Principles for National and Regional Guidelines on Cardiovascular Disease PreventionCirculation · 2004
  28. Should C-Reactive Protein Be Added to Metabolic Syndrome and to Assessment of Global Cardiovascular Risk?Circulation · 2004
  29. Obesity, Metabolic Syndrome, and Cardiovascular DiseaseThe Journal of Clinical Endocrinology & Metabolism · 2004
  30. Adipose Tissue Metabolites and Insulin Resistance in Nondiabetic Asian Indian MenThe Journal of Clinical Endocrinology & Metabolism · 2004
  31. Clinical Management of Metabolic SyndromeCirculation · 2004
  32. Definition of Metabolic SyndromeArteriosclerosis Thrombosis and Vascular Biology · 2004
  33. Clinical Management of Metabolic SyndromeArteriosclerosis Thrombosis and Vascular Biology · 2004
  34. Thiazolidinedione Use, Fluid Retention, and Congestive Heart FailureDiabetes Care · 2004
  35. Thiazolidinedione Use, Fluid Retention, and Congestive Heart FailureCirculation · 2003
  36. Genetic Polymorphism PC-1 K121Q and Ethnic Susceptibility to Insulin ResistanceThe Journal of Clinical Endocrinology & Metabolism · 2003
  37. From Vulnerable Plaque to Vulnerable PatientCirculation · 2003
  38. From Vulnerable Plaque to Vulnerable PatientCirculation · 2003
  39. The Metabolic SyndromeCirculation · 2003
  40. Elevated Plasma High-Sensitivity C-Reactive Protein Concentrations in Asian Indians Living in the United StatesThe Journal of Clinical Endocrinology & Metabolism · 2003
  41. Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering TherapyCirculation · 2002
  42. Can Statins Cause Chronic Low-Grade Myopathy?Annals of Internal Medicine · 2002
  43. Sex Steroid Hormones, Upper Body Obesity, and Insulin ResistanceThe Journal of Clinical Endocrinology & Metabolism · 2002
  44. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of StatinsStroke · 2002
  45. Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 Diabetes<subtitle>Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial</subtitle>Archives of Internal Medicine · 2002
  46. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 UpdateCirculation · 2002
  47. Statin Therapy in Older PersonsArchives of Internal Medicine · 2002
  48. Diabetes and Cardiovascular Disease Executive Summary Conference Proceeding for Healthcare Professionals From a Special Writing Group of the American Heart AssociationCirculation · 2002
  49. Sources of variability in genetic association studies: Insights from the analysis of hepatic lipase (LIPC)Human Mutation · 2002
  50. Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8Journal of Lipid Research · 2002